Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease

September 20, 2020 By The ASCO Post Staff

Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses primary results of the phase III JAVELIN trial of locally advanced squamous cell carcinoma of the head and neck, in which the immune checkpoint inhibitor avelumab was combined with chemoradiotherapy followed by avelumab maintenance. Although the study results were negative, Dr. Cohen suggests other regimens that may prove to be effective (Abstract 910O).

Related Content